Publications
24
Citations
7,238
Est. group size
—
Recurring co-author estimate
Active years
18
Publishing since 2008
Seung-Oe Lim's research focuses on how cancer cells evade the immune system, particularly through regulation of the immune checkpoint protein PD-L1 (a molecule tumors use to suppress immune attack) and related signaling pathways. This work explores molecular mechanisms such as protein modification, signaling cascades, and drug resistance to identify ways to improve cancer immunotherapy, especially in combination treatment strategies. Studies span multiple cancer types including breast, pancreatic, and liver cancer, often using findings to suggest biomarkers or therapeutic targets.
Publication output was concentrated between 2017-2021 with a cluster of papers, followed by a gap and only sporadic output (including one in 2025), indicating a slowing pace in recent years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Abstract 6011: Neoantigen peptide-loaded anti-CD40-spycatcher antibody as a novel cancer vaccine platform
Cancer Research · 2025
- TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis
Journal of Clinical Investigation · 2021
- Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade
Gut · 2019
- IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion
Journal of Clinical Investigation · 2019
- STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
Nature Communications · 2018
- Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer
Cancer Cell · 2018
- PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Clinical Cancer Research · 2017
- Rational combination of immunotherapy for triple negative breast cancer treatment
Chinese Clinical Oncology · 2017
- GSK3β inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers
Oncotarget · 2016
- Cancer Cell×3
- Cancer Research×3
- Nature Communications×2
- Journal of Clinical Investigation×2
- Clinical Cancer Research×1
- Zhe Li
Medicine · Purdue University West Lafayette
- Bikash Chandra Jena
Medicine · Purdue University West Lafayette
- Qi-En Wang
Medicine · The Ohio State University
- Sarah Steck
Medicine · The Ohio State University
- Katie Thies
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile